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OBJECTIVES The aim of this study was to evaluate the relationship between plasma oxidized low-density
lipoprotein (oxLDL), a marker of oxidative stress, and the prognosis of patients with chronic
congestive heart failure (CHF).
BACKGROUND Oxidative stress appears to play a role in the pathophysiology of CHF. We have recently
reported the usefulness of plasma oxLDL as a marker of oxidative stress in CHF patients with
dilated cardiomyopathy.
METHODS We measured the plasma level of oxLDL by sandwich enzyme-linked immunosorbent assay
using a specific monoclonal antibody against oxLDL in 18 age-matched normal subjects and
in 84 patients with chronic CHF (New York Heart Association functional class II to IV) and
monitored them prospectively for a mean follow-up period of 780 days.
RESULTS Plasma oxLDL level was significantly higher in severe CHF patients than in control subjects
and mild CHF patients. A significant negative correlation existed between the plasma level
of oxLDL and left ventricular ejection fraction (LVEF) and a significant positive correlation
between the plasma level of oxLDL and plasma norepinephrine level. Twenty-six patients
had cardiac events; 14 had cardiac death and 12 were hospitalized for heart failure or other
cardiovascular events. Among 10 variables including LVEF and neurohumoral factors, only
high plasma levels of brain natriuretic peptide and oxLDL were shown to be independent
predictors of mortality.
CONCLUSIONS These results indicate that the plasma level of oxLDL is a useful predictor of mortality in
patients with CHF, suggesting that oxidative stress plays an important role in the
pathophysiology of CHF. (J Am Coll Cardiol 2002;39:957–62) © 2002 by the American
College of Cardiology Foundation
Recent studies suggest that free radicals are increased in the
failing myocardium and may be important contributors to
the deterioration of decompensating myocardium (1–3). A
chronic increase in myocardial oxidative stress is capable of
causing subcellular abnormalities, and this may lead to
cardiomyopathic changes, depressed contractile function
and failure (4,5). Thus, oxidative stress may be an important
susceptibility factor for congestive heart failure (CHF) (6,7).
Several plasma biochemical markers of oxidative stress have
been reported to be increased in chronic CHF patients
(3,8,9), suggesting that oxidative stress is one of the impor-
tant mechanisms in CHF progression. Because it is difficult
to measure free radicals directly in humans, indirect markers
of their activity have been used. Recently, a sensitive and
specific method of measuring very low concentrations of
oxidized low-density lipoprotein (oxLDL) was established
(10,11). We have reported that the plasma level of oxLDL
is a useful marker of oxidative stress in the failing heart of
CHF patients with dilated cardiomyopathy (DCM) (12),
suggesting that left ventricular dysfunction may be partly
due to oxidative stress in patients with DCM. However, to
our knowledge, there have been no reports about the
relationship between plasma markers of oxidative stress and
the prognosis of CHF.
Therefore, we evaluated the relationship between the
plasma level of oxLDL and the other markers of the severity
of CHF, and we assessed whether plasma oxLDL can
provide prognostic information independent of clinical and
neurohumoral factors previously associated with a poor
prognosis in CHF patients.
METHODS
Patients. Eighty-four consecutive patients with mild to
severe CHF with DCM or ischemic cardiomyopathy (left
ventricular ejection fraction [LVEF] 45%, New York
Heart Association [NYHA] functional class II to IV) who
visited our hospital between August 1998 and September
1999 were entered into this study. Patients with infection,
inflammatory diseases, malignancy, renal failure, congenital
malformations of the heart or vessels, angina pectoris or a
history of acute myocardial infarction (MI) within the past
three months were excluded. The subjects were 63 men and
21 women ranging in age from 17 to 85 years (mean 63.0
1.5 years); 49 patients with ischemic cardiomyopathy had
an MI 3 months before the study; 35 had DCM diag-
nosed as previously reported (12). Fifty patients were
classified as NYHA functional class II, 26 patients as class
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III and 8 patients as class VI. We also selected 18 control
subjects (17 to 79 years, mean 58.9  3.1 years) whose
hearts were normal on cardiac catheterization and coronary
angiography. None of the control subjects had histories of
hypertension, diabetes mellitus, hypercholesterolemia or
smoking. Informed consent was obtained from all patients
before participating in the study, and the protocol was
approved by the Human Investigations Committee of our
institution.
Study protocol. All patients had rested in bed in the supine
position for at least 30 min early in the morning. Blood
samples for measuring plasma level of oxLDL, norepineph-
rine (NE), brain natriuretic peptide (BNP) and serum levels
of total cholesterol, high-density lipoprotein cholesterol,
low-density lipoprotein (LDL) cholesterol and triglycerides
were collected from the peripheral vein. The LVEF was
measured by echocardiography using the biplane disc sum-
mation method (Simpson’s rule) or left ventriculography in
a blinded fashion. Then, the 84 patients were entered and
followed prospectively. All surviving patients were moni-
tored prospectively for 589 days, for a mean follow-up
period of 780 15.6 days (range 589 to 984 days). The end
points, which were judged independently by researchers,
were cardiac death (worsening CHF, lethal MI or sudden
death) or hospitalization for worsening CHF, MI or fatal
arrhythmia.
Measurements of oxLDL, NE and BNP. Blood for mea-
surement of the plasma level of oxLDL was placed into a
plain tube, centrifuged at 3,000 rpm for 15 min at 4°C, and
the plasma thus obtained was stored at 4°C until assayed.
Plasma oxLDL levels were measured using a specific im-
munometric assay for human oxLDL using a kit (Kyowa
Medex, Tokyo, Japan) (10,11), which employed a modifi-
cation of a method previously reported (10). Briefly, this
assay system uses two antibodies against human oxLDL,
one recognizing a monoclonal antibody against oxidized
phosphatidylcholine (10) and the other a polyclonal anti-
body against human apolipoprotein B, respectively, and
measures oxLDL by sandwiching it between the two anti-
bodies (11,12). Plasma concentration of BNP was measured
with a specific immunoradiometric assay using a commercial
kit (Shionogi, Osaka, Japan) as previously reported (13).
Plasma level of NE was measured with high-performance
liquid chromatography as previously reported (13).
Statistical analysis. All results are expressed as the mean
SEM. Univariate analyses were performed using the Stu-
dent t test. Comparisons between multiple groups were
determined by one-way analysis of variance with the Scheffe´
F test. Categorical data were compared against a chi-square
distribution. Linear regression analysis was used to deter-
mine the relationship between continuous variables. To
ascertain whether measurement of plasma level of oxLDL is
useful for predicting morbidity and mortality in patients
with chronic CHF, 10 variables were entered into a Cox
proportional hazard analysis. Kaplan-Meier analysis was
performed on the cumulative cardiac event-free rates in
patients with chronic CHF stratified into two groups based
on the median plasma oxLDL level. A value of p  0.05
was considered significant.
RESULTS
Clinical characteristics. There was no difference in age,
gender or plasma levels of total cholesterol, LDL choles-
terol, HDL cholesterol or triglycerides among control sub-
jects, mild CHF patients (NYHA functional class II) and
severe CHF patients (NYHA functional class III or IV)
(Table 1). The mean LVEF was significantly lower in
patients with severe CHF than in patients with mild CHF.
There was no difference in etiology and therapy between
patients with mild CHF and patients with severe CHF.
Relationship between plasma oxLDL and the severity of
CHF. No significant correlation existed between the
plasma oxLDL and plasma levels of total cholesterol, LDL
cholesterol, HDL cholesterol or triglycerides in control
subjects and patients with CHF. The plasma oxLDL level
was significantly higher in severe CHF patients than in
control subjects and mild CHF patients (Fig. 1). A signif-
icant negative correlation was observed between the plasma
level of oxLDL and LVEF (Fig. 2A). A significant positive
correlation existed between the plasma level of oxLDL and
plasma NE level (Fig. 2B).
Characteristics of 84 patients followed with CHF. All of
the 84 enrolled patients were successfully followed (Table
2). During the follow-up period, 14 patients died and 12
were hospitalized due to cardiac event. The cause of death
was worsening CHF in 12 patients and sudden death in 2
others. The causes of rehospitalization were worsening
CHF in 11 patients and fatal arrhythmia in 1 patient. No
differences existed between survivors and nonsurvivors by
age, gender, etiology, coronary risk factors, LVEF or treat-
ments. Plasma levels of oxLDL, BNP and NE were
significantly higher in nonsurvivors than in survivors.
High plasma level of oxLDL as a predictor of morbidity
and mortality. By univariate analysis, LVEF, NYHA
functional class, plasma levels of BNP, NE and oxLDL
were significant predictors of mortality. Stepwise multivar-
iate analysis showed that high plasma levels of both BNP
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  congestive heart failure
DCM  dilated cardiomyopathy
HDL  high-density lipoprotein
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NE  norepinephrine
NYHA  New York Heart Association
oxLDL  oxidized low-density lipoprotein
TBARS  thiobarbituric acid-reacting substances
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and oxLDL were significant independent predictors for
mortality (Table 3) and also for morbidity and mortality. In
patients with plasma oxLDL 12.2 U/ml, survival rates, as
determined by Kaplan-Meier analysis, were significantly 1.9
times higher (p  0.004) and the cardiac event-free curve
was significantly 2.5 times higher (p  0.0017) (Fig. 3).
There was no significant difference in the area under the
receiver operating characteristic curves for plasma BNP level
and plasma oxLDL level, confirming the equal prognostic
values of plasma BNP level and plasma oxLDL level in
predicting mortality and morbidity.
DISCUSSION
As a marker of oxidative stress, plasma level of oxLDL was
measured using a specific monoclonal antibody against
oxLDL in 84 patients with chronic CHF; patients were
monitored prospectively. A high plasma level of oxLDL
(p  0.0006) was shown to be an important predictor of
mortality independent of clinical and neurohumoral factors
previously associated with a poor prognosis in patients with
CHF. Therefore, we demonstrated that the plasma level of
oxLDL is a useful predictor of mortality in patients with
CHF, suggesting that oxidative stress plays an important
role in the pathophysiology of CHF.
Plasma level of oxLDL increased in patients with CHF.
In this study, plasma oxLDL level increased in the periph-
eral vein in patients with chronic CHF caused by DCM or
ischemic cardiomyopathy. The elevated level of plasma
oxLDL in the peripheral vein may reflect the increased
oxidation status in the failing myocardium or poorly per-
fused peripheral muscles in patients with CHF. We recently
reported that the plasma level of oxLDL measured in the
coronary sinus in DCM patients with CHF was signifi-
cantly higher than that in the aortic root, and there was no
difference in the plasma oxLDL level between in the aortic
root and in the femoral vein, suggesting that the source of
the increase in plasma oxLDL is of myocardial origin rather
than peripheral origin. In contrast, thiobarbituric acid-
reacting substances (TBARS) measured in the same pa-
tients did not show an increase in plasma level as plasma
oxLDL did, suggesting that the plasma oxLDL is a sensi-
tive marker of oxidative stress in the heart of DCM patients,
and free radicals such as superoxide produced in the failing
myocardium may oxidize LDL cholesterol (12).
The plasma level of oxLDL increased with the severity of
Table 1. Clinical Characteristics
Characteristics
Control
(n  18)
All Patients
(n  84)
Mild CHF
(n  50)
Severe CHF
(n  34)
Age (yrs) 58.9  3.1 63  1.5 63.8  1.7 61.9  2.8
Gender (M/F) 14/4 63/21 40/10 23/11
HR (beats/min) 67.7  3.5 72.5  1.1 70.2  1.5 76.0  1.7‡
MBP (mm Hg) 80.7  1.3 76.6  0.6† 76.5  0.6‡ 76.8  1.1‡
LVEF (%) 66.1  1.5 30.7  1.0* 34.6  1.1* 24.9  1.4*§
LVEDVI (ml/m2) 85.9  4.8 147  4.4* 130.0  3.4* 171.2  7.9*§
BNP (pg/ml) 12.3  1.4 334  42** 161.5  21.7‡ 586.4  82.2*§
NE (pg/ml) 194.4  12.3 592  67.4† 415.3  37.5 850.7  147.3**¶
oxLDL (U/ml) 9.5  0.8 14.3  1‡ 11.3  0.9 18.8  1.7**§
TC (mg/dl) 174  5.8 180  4.1 185  5.3 173  6.3
TG (mg/dl) 93  11.8 117  5.7 125  5.7 104  9.9
HDL-C (mg/dl) 44.1  2.9 39.8  1.4 40.8  2.0 38.2  2.0
LDL-C (mg/dl) 111  5.6 114  3.4 114  4.6 114  5.3
Etiology (ICM/DCM) — 49/35 30/20 19/15
Risk factors
Diabetes mellitus — 15 (18%) 10 (20%) 5 (15%)
Hypertension — 24 (29%) 16 (32%) 8 (24%)
Hypercholesterolemia — 22 (26%) 15 (30%) 7 (21%)
Smoking — 16 (19%) 11 (22%) 5 (15%)
Treatments
Diuretics — 58 (69%) 33 (66%) 25 (74%)
Digitalis — 34 (40%) 21 (42%) 13 (38%)
ACE inhibitors or ARB — 69 (82%) 41 (82%) 28 (82%)
Beta-blockers — 31 (37%) 22 (44%) 9 (26%)
Vasodilators — 34 (41%) 18 (36%) 16 (47%)
Statins — 18 (21%) 13 (26%) 5 (15%)
*p  0.0001 vs. control. **p  0.001 vs. control. †p  0.01 vs. control. ‡p  0.05 vs. control. §p  0.0001 vs. mild. ¶p  0.01
vs. mild.
ACE  angiotensin-converting enzyme; ARB  angiotensin II type 1 receptor blockers; BNP  brain natriuretic peptide;
CHF congestive heart failure; DCM dilated cardiomyopathy; HDL-C high-density lipoprotein cholesterol; HR heart
rate; ICM ischemic cardiomyopathy; LDL-C low-density lipoprotein cholesterol; LVEDVI left ventricular end-diastolic
volume index; LVEF  left ventricular ejection fraction; MBP  mean blood pressure; NE  norepinephrine; oxLDL 
oxidized low-density lipoprotein; TC  total cholesterol; TG  triglycerides.
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CHF in patients with DCM and ischemic cardiomyopathy.
In patients with coronary artery disease, the circulating
oxLDL may also be derived from coronary atherosclerotic
lesions, especially foam-cell-rich unstable plaques in acute
coronary syndrome, because it was not increased in patients
with stable coronary artery disease (14).
In the present study, plasma oxLDL was measured using
the same antibody as the previous study (14), and all 49
patients with ischemic cardiomyopathy had an MI 3
months before the study, and had no clinical signs of
ischemia such as chest pain and diagnostic ST-T changes on
electrocardiogram by exercise test after MI. Therefore, the
increased plasma oxLDL in patients with ischemic cardio-
myopathy in the present study was considered mainly due to
CHF. Indeed, no ischemic cardiac events were associated
with acute coronary syndrome in most patients during the
follow-up period.
Plasma level of oxLDL as an independent prognostic
predictor in patients with chronic CHF. Increased bio-
chemical markers of oxidative stress measured in peripheral
blood and pericardial effusion in patients with CHF have
been reported to correlate with functional class (9,15) and
inversely with LVEF (3,12). Our findings are consistent
with those reports. Hence, it is suggested that oxidative
stress is an important factor in the progression of heart
failure. However, the relationship between the biochemical
markers of oxidative stress and the prognosis of CHF
remains unknown. Our study reports for the first time
that the plasma level of oxLDL, a clinical marker of
oxidative stress, may be a useful prognostic predictor in
patients with CHF. In the present study, plasma levels
of BNP and NE and low LVEF were prognostic factors
in CHF by univariate analysis as previously reported (16,17).
However, according to stepwise multivariate analysis, a high
plasma level of oxLDL was a significant independent predictor
Figure 1. Plasma oxidized low-density lipoprotein (oxLDL) concentration
in 18 control subjects, 50 patients with mild congestive heart failure (CHF)
(New York Heart Association [NYHA] functional class II) and 34 patients
with severe CHF (NYHA functional class III or IV). Mild CHF 
NYHA functional class II; severe CHF  NYHA functional class III or
IV. Triangles  control subjects; solid circles  patients with dilated
cardiomyopathy; open circles  patients with ischemic cardiomyopathy.
Figure 2. Correlation between the plasma level of oxidized low-density lipoprotein (oxLDL) and left ventricular ejection fraction (LVEF) (A), and the
plasma level of norepinephrine (NE) (B).
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of mortality, suggesting that oxidative stress is an important
prognostic factor in patients with CHF.
Recent reports suggest that myocardial injury caused by
free radicals lead to depressed contractile function and
myocardial remodeling (4,5). Many factors related to the
progression of heart failure, such as neurohumoral factors,
including catecholamine (18), angiotensin II (19), cytokines
(20) and myocardial mechanical stretch (21), which can
induce natriuretic peptide production, are closely linked to
free radical formation and oxidative stress at the cellular and
molecular levels. Angiotensin-converting enzyme inhibitors
and beta-blockers, which have been proven to reduce
mortality in patients with chronic CHF, were reported to
protect the failing heart partly because of the reduction of
myocardial oxidative stress.
Study limitations. In the present study, we did not mea-
sure other clinical biochemical markers of oxidative stress.
Further studies are needed to determine the comparative
prognostic value of other markers; however, plasma oxLDL
was a sensitive marker compared with TBARS as previously
reported (12). Further studies are needed to clarify the role
of repetitive measurement of plasma oxLDL before and
after treatments, such as carvedilol, angiotensin-converting
enzyme inhibitors, and antioxidants in determining the
prognosis of CHF patients.
Conclusions. The plasma level of oxLDL, a marker of
oxidative stress, increased with the severity of CHF. A
significant correlation existed between the plasma level of
oxLDL, LVEF and NE. A high plasma oxLDL level is an
independent risk factor for mortality and morbidity in
Table 2. Characteristics of 84 Patients With Chronic Congestive Heart Failure—Survivors and Nonsurvivors With and Without
Cardiac Event
Characteristics
Survivors
(n  70)
Nonsurvivors
(n  14) p Value
Cardiac Event ()
(n  58)
Cardiac Event ()
(n  26) p Value
Age (yrs) 62.3  1.7 66.9  3.2 NS 63.1  1.9 62.9  2.5 NS
Gender (M/F) 54/16 9/5 NS 44/14 19/7 NS
NYHA functional class 2.36  0.07 3.21  0.19  0.0001 2.29  0.07 2.96  0.14  0.0001
LVEF (%) 31.5  1.1 26.7  2.3 NS 32.8  1.1 25.9  1.6 0.01
oxLDL (U/ml) 12.6  0.8 23.1  3.0  0.0001 11.5  0.8 20.5  2.0  0.0001
BNP (pg/ml) 240  33 799  141  0.0001 195  33 642  90  0.0001
NE (pg/ml) 465  37 1227  317  0.0001 446  42 915  183 0.001
Etiology (ICM/DCM) 44/26 5/9 NS 37/21 12/14 NS
Risk factors
Diabetes mellitus 13 (19%) 2 (14%) NS 12 (21%) 3 (12%) NS
Hypertension 19 (27%) 5 (36%) NS 19 (33%) 5 (15%) NS
Hypercholesterolemia 17 (24%) 5 (36%) NS 14 (24%) 8 (31%) NS
Smoking 13 (19%) 3 (21%) NS 13 (22%) 3 (12%) NS
Treatments
Diuretics 48 (69%) 10 (71%) NS 36 (62%) 22 (85%) NS
Digitalis 29 (41%) 5 (36%) NS 23 (40%) 11 (42%) NS
ACE inhibitors or ARB 58 (83%) 11 (79%) NS 48 (83%) 21 (81%) NS
Beta-blockers 27 (39%) 4 (29%) NS 19 (33%) 12 (46%) NS
Vasodilators 25 (36%) 9 (64%) NS 21 (36%) 13 (50%) NS
Statins 14 (20%) 4 (29%) NS 12 (21%) 6 (23%) NS
ACE  angiotensin-converting enzyme; ARB  angiotensin II type 1 receptor blockers; BNP  brain natriuretic peptide; DCM  dilated cardiomyopathy; ICM  ischemic
cardiomyopathy; LVEF  left ventricular ejection fraction; NE  norepinephrine; NYHA  New York Heart Association; oxLDL  oxidized low-density lipoprotein.
Table 3. Univariate and Multivariate Predictors of Mortality of 84 Patients With Congestive
Heart Failure According to Cardiovascular Death
Variables
Univariate
Chi-Square p Value
Multivariate
Chi-Square p Value
Age (yrs) 1.313 0.2518 0.923 0.3366
Gender (male  1) 0.975 0.3235 0.007 0.9352
Ischemic etiology (yes  1) 3.535 0.0601 1.895 0.1686
Diabetes mellitus (yes  1) 0.132 0.7161 0.572 0.4493
Hypercholesterolemia (yes  1) 0.857 0.3546 1.881 0.1703
LVEF (%) 4.189 0.0407 0.388 0.5336
NYHA functional class 24.219  0.0001 1.299 0.2543
BNP (pg/ml) 36.77  0.0001 13.65 0.0002
NE (pg/ml) 42.087  0.0001 2.527 0.1119
oxLDL (U/ml) 26.966  0.0001 11.787 0.0006
BNP  brain natriuretic peptide; LVEF  left ventricular ejection fraction; NE  norepinephrine; NYHA  New York Heart
Association; oxLDL  oxidized low-density lipoprotein.
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patients with CHF, suggesting that oxidative stress plays an
important role in the pathophysiology of CHF.
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